PMID- 34452364
OWN - NLM
STAT- MEDLINE
DCOM- 20220202
LR  - 20220202
IS  - 1999-4915 (Electronic)
IS  - 1999-4915 (Linking)
VI  - 13
IP  - 8
DP  - 2021 Jul 29
TI  - Exosome-Based Vaccines: Pros and Cons in the World of Animal Health.
LID - 10.3390/v13081499 [doi]
LID - 1499
AB  - Due to the emergence of antibiotic resistance and new and more complex diseases 
      that affect livestock animal health and food security, the control of epidemics 
      has become a top priority worldwide. Vaccination represents the most important 
      and cost-effective measure to control infectious diseases in animal health, but 
      it represents only 23% of the total global animal health market, highlighting the 
      need to develop new vaccines. A recent strategy in animal health vaccination is 
      the use of extracellular vesicles (EVs), lipid bilayer nanovesicles produced by 
      almost all living cells, including both prokaryotes and eukaryotes. EVs have been 
      evaluated as a prominent source of viral antigens to elicit specific immune 
      responses and to develop new vaccination platforms as viruses and EVs share 
      biogenesis pathways. Preliminary trials with lymphocytic choriomeningitis virus 
      infection (LCMV), porcine reproductive and respiratory syndrome virus (PRRSV), 
      and Marek's disease virus (MDV) have demonstrated that EVs have a role in the 
      activation of cellular and antibody immune responses. Moreover, in parasitic 
      diseases such as Eimeria (chickens) and Plasmodium yoelii (mice) protection has 
      been achieved. Research into EVs is therefore opening an opportunity for new 
      strategies to overcome old problems affecting food security, animal health, and 
      emerging diseases. Here, we review different conventional approaches for vaccine 
      design and compare them with examples of EV-based vaccines that have already been 
      tested in relation to animal health.
FAU - Montaner-Tarbes, Sergio
AU  - Montaner-Tarbes S
AD  - Innovex Therapeutics SL, 08916 Badalona, Spain.
FAU - Fraile, Lorenzo
AU  - Fraile L
AUID- ORCID: 0000-0002-8980-5862
AD  - Agrotecnio Center, Department of Animal Science, University of Lleida, 25198 
      Lleida, Spain.
FAU - Montoya, Maria
AU  - Montoya M
AUID- ORCID: 0000-0002-5703-7360
AD  - Centro de Investigaciones Biologicas Margarita Salas (CIB-CSIC), Ramiro de Maeztu 
      9, 29040 Madrid, Spain.
FAU - Del Portillo, Hernando
AU  - Del Portillo H
AD  - Innovex Therapeutics SL, 08916 Badalona, Spain.
AD  - ICREA at ISGlobal, Barcelona Institute for Global Health and IGTP, German Trias I 
      Pujol Health Research Institute, 08916 Badalona, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210729
PL  - Switzerland
TA  - Viruses
JT  - Viruses
JID - 101509722
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Animals
MH  - Chickens/immunology
MH  - Exosomes/genetics/*immunology
MH  - Herpesvirus 2, Gallid/immunology
MH  - Poultry Diseases/classification/immunology/prevention & control
MH  - Swine/immunology
MH  - Swine Diseases/classification/immunology/prevention & control
MH  - Vaccination/*veterinary
MH  - Viral Vaccines/administration & dosage/genetics/*immunology
MH  - Virus Diseases/immunology/*prevention & control/*veterinary
PMC - PMC8402771
OTO - NOTNLM
OT  - extracellular vesicles
OT  - vaccines
OT  - viral diseases
COIS- S.M.-T. is an employee of Innovex Therapeutics S.L. (ITSL). M.M., L.F. and H.D.P. 
      are ITSL shareholders.
EDAT- 2021/08/29 06:00
MHDA- 2022/02/03 06:00
PMCR- 2021/07/29
CRDT- 2021/08/28 01:06
PHST- 2021/05/21 00:00 [received]
PHST- 2021/07/26 00:00 [revised]
PHST- 2021/07/27 00:00 [accepted]
PHST- 2021/08/28 01:06 [entrez]
PHST- 2021/08/29 06:00 [pubmed]
PHST- 2022/02/03 06:00 [medline]
PHST- 2021/07/29 00:00 [pmc-release]
AID - v13081499 [pii]
AID - viruses-13-01499 [pii]
AID - 10.3390/v13081499 [doi]
PST - epublish
SO  - Viruses. 2021 Jul 29;13(8):1499. doi: 10.3390/v13081499.